Abstract
The taxanes, paclitaxel and docetaxel, are among the most promising new agents in the treatment of breast cancer. Responses are routinely seen in > 30% of patients with metastatic disease, including those who have previously received anthracyclines. Combination therapy has increased response rates but as yet has not improved the overall survival of patients with metastatic disease. Improved survival with the addition of paclitaxel to standard adjuvant therapy reported in a recently completed trial suggests the true impact of the taxanes has not yet been realized.
MeSH terms
-
Antibiotics, Antineoplastic / administration & dosage
-
Antineoplastic Agents, Phytogenic / administration & dosage
-
Antineoplastic Agents, Phytogenic / adverse effects
-
Antineoplastic Agents, Phytogenic / pharmacology
-
Antineoplastic Agents, Phytogenic / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Bone Marrow Diseases / chemically induced
-
Breast Neoplasms / drug therapy*
-
Chemotherapy, Adjuvant
-
Clinical Trials as Topic
-
Docetaxel
-
Drug Administration Schedule
-
Drug Resistance, Neoplasm
-
Female
-
Humans
-
Neoplasm Metastasis
-
Neoplasm Proteins / drug effects
-
Paclitaxel / administration & dosage
-
Paclitaxel / adverse effects
-
Paclitaxel / analogs & derivatives*
-
Paclitaxel / pharmacology
-
Paclitaxel / therapeutic use*
-
Palliative Care
-
Survival Analysis
-
Taxoids*
-
Tubulin / drug effects
-
Vinca Alkaloids / administration & dosage
-
Vinca Alkaloids / pharmacology
Substances
-
Antibiotics, Antineoplastic
-
Antineoplastic Agents, Phytogenic
-
Neoplasm Proteins
-
Taxoids
-
Tubulin
-
Vinca Alkaloids
-
Docetaxel
-
Paclitaxel